BASKING RIDGE, N.J. and MEMPHIS, Tenn., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development ...
Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature Patients ...
Please provide your email address to receive an email when new articles are posted on . There are no approved treatments, so providers use off-label prescriptions. 30.4% did not know the three most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results